220 related articles for article (PubMed ID: 33683854)
1. A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.
Sun H; Zhong Y; Zhu X; Liao H; Lee J; Chen Y; Ma L; Ren J; Zhao M; Tu M; Li F; Zhang H; Tian M; Ling D
ACS Nano; 2021 Mar; 15(3):5263-5275. PubMed ID: 33683854
[TBL] [Abstract][Full Text] [Related]
2. Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model.
Zhang ZH; Wu QY; Zheng R; Chen C; Chen Y; Liu Q; Hoffmann PR; Ni JZ; Song GL
J Neurosci; 2017 Mar; 37(9):2449-2462. PubMed ID: 28137967
[TBL] [Abstract][Full Text] [Related]
3. Tetrandrine ameliorates cognitive deficits and mitigates tau aggregation in cell and animal models of tauopathies.
Tong BC; Huang AS; Wu AJ; Iyaswamy A; Ho OK; Kong AH; Sreenivasmurthy SG; Zhu Z; Su C; Liu J; Song J; Li M; Cheung KH
J Biomed Sci; 2022 Oct; 29(1):85. PubMed ID: 36273169
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial bioenergetics stimulates autophagy for pathological tau clearance in tauopathy neurons.
Jia N; Ganesan D; Guan H; Jeong YY; Han S; Nissenbaum M; Kusnecov AW; Cai Q
bioRxiv; 2024 Feb; ():. PubMed ID: 38405759
[TBL] [Abstract][Full Text] [Related]
5. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
[TBL] [Abstract][Full Text] [Related]
6. Autophagy and Tau Protein.
Hamano T; Enomoto S; Shirafuji N; Ikawa M; Yamamura O; Yen SH; Nakamoto Y
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299093
[TBL] [Abstract][Full Text] [Related]
7. Spleen tyrosine kinase (SYK) blocks autophagic Tau degradation
Schweig JE; Yao H; Coppola K; Jin C; Crawford F; Mullan M; Paris D
J Biol Chem; 2019 Sep; 294(36):13378-13395. PubMed ID: 31324720
[TBL] [Abstract][Full Text] [Related]
8. Autophagic degradation of tau in primary neurons and its enhancement by trehalose.
Krüger U; Wang Y; Kumar S; Mandelkow EM
Neurobiol Aging; 2012 Oct; 33(10):2291-305. PubMed ID: 22169203
[TBL] [Abstract][Full Text] [Related]
9. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.
Matsuoka Y; Jouroukhin Y; Gray AJ; Ma L; Hirata-Fukae C; Li HF; Feng L; Lecanu L; Walker BR; Planel E; Arancio O; Gozes I; Aisen PS
J Pharmacol Exp Ther; 2008 Apr; 325(1):146-53. PubMed ID: 18199809
[TBL] [Abstract][Full Text] [Related]
10. The mTOR Inhibitor Rapamycin Mitigates Perforant Pathway Neurodegeneration and Synapse Loss in a Mouse Model of Early-Stage Alzheimer-Type Tauopathy.
Siman R; Cocca R; Dong Y
PLoS One; 2015; 10(11):e0142340. PubMed ID: 26540269
[TBL] [Abstract][Full Text] [Related]
11. Membrane estrogen receptor ERα activation improves tau clearance via autophagy induction in a tauopathy cell model.
Costa AJ; Oliveira RB; Wachilewski P; Nishino MS; Bassani TB; Stilhano RS; Cerutti JM; Nozima B; Porto CS; Pereira GJDS; Ramirez AL; Smaili SS; Ureshino RP
Brain Res; 2022 Nov; 1795():148079. PubMed ID: 36088959
[TBL] [Abstract][Full Text] [Related]
12. Repeated ultrasound treatment of tau transgenic mice clears neuronal tau by autophagy and improves behavioral functions.
Pandit R; Leinenga G; Götz J
Theranostics; 2019; 9(13):3754-3767. PubMed ID: 31281511
[TBL] [Abstract][Full Text] [Related]
13. Current strategies for the treatment of Alzheimer's disease and other tauopathies.
Dickey CA; Petrucelli L
Expert Opin Ther Targets; 2006 Oct; 10(5):665-76. PubMed ID: 16981824
[TBL] [Abstract][Full Text] [Related]
14. Ginkgo biloba Extract EGb 761 and Its Specific Components Elicit Protective Protein Clearance Through the Autophagy-Lysosomal Pathway in Tau-Transgenic Mice and Cultured Neurons.
Qin Y; Zhang Y; Tomic I; Hao W; Menger MD; Liu C; Fassbender K; Liu Y
J Alzheimers Dis; 2018; 65(1):243-263. PubMed ID: 30010136
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological doses of melatonin impede cognitive decline in tau-related Alzheimer models, once tauopathy is initiated, by restoring the autophagic flux.
Luengo E; Buendia I; Fernández-Mendívil C; Trigo-Alonso P; Negredo P; Michalska P; Hernández-García B; Sánchez-Ramos C; Bernal JA; Ikezu T; León R; López MG
J Pineal Res; 2019 Aug; 67(1):e12578. PubMed ID: 30943316
[TBL] [Abstract][Full Text] [Related]
16. Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer's disease mouse and reduces human P301L-tau content at the presymptomatic stage.
Shibuya Y; Niu Z; Bryleva EY; Harris BT; Murphy SR; Kheirollah A; Bowen ZD; Chang CCY; Chang TY
Neurobiol Aging; 2015 Jul; 36(7):2248-2259. PubMed ID: 25930235
[TBL] [Abstract][Full Text] [Related]
17. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
Navarrete LP; Pérez P; Morales I; Maccioni RB
Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
[TBL] [Abstract][Full Text] [Related]
18. Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease.
Reddy PH; Oliver DM
Cells; 2019 May; 8(5):. PubMed ID: 31121890
[TBL] [Abstract][Full Text] [Related]
19. Metformin attenuates diabetes-induced tau hyperphosphorylation in vitro and in vivo by enhancing autophagic clearance.
Chen JL; Luo C; Pu D; Zhang GQ; Zhao YX; Sun Y; Zhao KX; Liao ZY; Lv AK; Zhu SY; Zhou J; Xiao Q
Exp Neurol; 2019 Jan; 311():44-56. PubMed ID: 30219731
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of TLR4 Attenuates Alzheimer's Disease-Related Symptoms and Pathology in Tau-Transgenic Mice.
Qin Y; Liu Y; Hao W; Decker Y; Tomic I; Menger MD; Liu C; Fassbender K
J Immunol; 2016 Oct; 197(8):3281-3292. PubMed ID: 27605009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
